Tegore Emcure was the first private equity investment by a Blackstone-managed fund in India. For the nine months period ended December Reproduction of news articles, photos, videos or any other content in whole or drnp part in any form or medium without express writtern permission of moneycontrol. Book running lead managers to the issue include Bank of America Merrill Lynch. Emcurw areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients. Fortis again pushes back date rmcure complete RHT Health deal; auditor resigns. The issue also involves a secondary sale 2.

Author:Yoshakar Nijind
Language:English (Spanish)
Published (Last):13 August 2005
PDF File Size:13.76 Mb
ePub File Size:9.77 Mb
Price:Free* [*Free Regsitration Required]

The Issue comprises a fresh issue of Equity Shares aggregating up to Rs. The Company is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.

Its core strength lies in in-house development and manufacturing of differentiated pharmaceutical products. The Company focuses its research and development efforts on developing a portfolio of differentiated products across several platforms, including chiral molecules, biosimilars and novel drug delivery systems.

The Company commercializes its products through a combination of its own marketing and distribution infrastructure across geographies as well as relationships with multi-national pharmaceutical companies. The Company believes its competitive advantage in the domestic market lies in its established presence in all major therapeutic areas.

It has a pan India marketing and distribution presence with a field force of more than 4, personnel, as of March 31, The Company has a well-diversified income base in terms of geographies, therapeutic areas and business segments within the pharmaceutical industry.

The Company has its own sales and marketing infrastructure in the United States through its subsidiary, Heritage. The Company also sells its portfolio of branded generic products to the rest of world. Its products are currently shipped to over 65 countries, where it has established its presence by focusing on important alliances with local and multi-national companies. The Company has subsidiaries in Brazil, Dubai, Nigeria, Singapore and South Africa and branch offices in Morocco and Russia, which play an important role in its international operations.

It operates nine manufacturing facilities, eight of which are located in India and one in the United States. These facilities are capable of producing APIs and pharmaceutical products encompassing a wide range of dosage forms including oral solids, oral liquids, soft gelatin capsules and injectables both liquid and lyophilized.

The manufacturing capability of the Company allows it to manufacture complex products, including cytotoxic products. The Company also manufactures products for certain pharmaceutical multi-national companies and the Company believes that it has emerged as a technologically dependable and quality conscious company of choice for these companies. The Company is led by highly qualified and experienced management team and the board of directors.

Related Story.


Emcure Pharma files DRHP with SEBI

Today, Blackstone announced that one of its affiliated private equity entities based in Mauritius had entered into an agreement to sell its equity stake in Pune-based Emcure Pharmaceuticals Limited to Bain Capital. Emcure is engaged in developing, manufacturing and marketing a well-diversified range of pharmaceutical products globally. In addition to providing growth capital to expand our business multi-fold, they also shared strategic insights to manage our fast growing business effectively. We are delighted that we have lived up to the faith reposed in us by Blackstone. We are also delighted to welcome a prestigious firm like Bain Capital and look forward to reaching greater heights in partnership with them. Since our investment, the company has significantly strengthened its position in the Indian pharmaceutical market and has established a strong presence in the US and other semi-regulated markets. Going forward, we believe Emcure will continue to build on its strong platform and continue its rapid growth trajectory.



Last Updated: Jan 18, , The company, incorporated in , makes a range of drugs such as Asomex, used to treat blood pressure. Cardiology, gynaecology and anti-infective medicines account for a bulk of its portfolio. Emcure did not comment on the deal. A questionnaire sent to Marcan Pharmaceuticals went unanswered until press time.


Emcure Pharmaceuticals files for IPO; Blackstone to part exit

The issue also involves a secondary sale 2. Blackstone has invested Rs crore in Emcure through convertible shares and currently holds a The PE firm is selling around 1. Book running lead managers to the issue include Bank of America Merrill Lynch. Another pharmaceutical firm which filed for public offering recently was Intas Pharmaceuticals.

Related Articles